Trial register facet
Trial records in obesity and overweight in adults — page 2
208 records bearing on obesity and overweight in adults.
Showing 0 records on this page
Records
208 documents · page 2 of 9
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| REDEFINE-2-ADHERENCEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Observational | — | 2025 | Very low |
| GLORY-1-OLEprogramme record | Mazdutide | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| SURMOUNT-4 | Tirzepatide | Phase 3 | Reported | Randomised withdrawal | 670 | 2024 | High |
| SURMOUNT-OSA-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | High |
| SURMOUNT-OSA-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | High |
| SUMMIT | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 731 | 2024 | Moderate |
| SURVO-PH2-OBESITY | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 387 | 2024 | Moderate |
| PETRE-PH1B | Petrelintide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Low |
| REIMAGINE-1 | Amycretin | Phase 1 | Reported | Phase 1 ascending dose | 125 | 2024 | Low |
| MARITIDE-PH2-OBESITY | Maridebart cafraglutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 592 | 2024 | Low |
| SURMOUNT-4-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURMOUNT-OSA-1-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2024 | Very low |
| SURMOUNT-OSA-2-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-BIOMARKERprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| MARITIDE-PH2-OBESITY-HEPATIC-IMPprogramme record | Maridebart cafraglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURVO-PH2-OBESITY-ELDERLYprogramme record | Survodutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| PETRE-PH1B-ADHERENCEprogramme record | Petrelintide | Phase 1 | Reported | Observational | — | 2024 | Very low |
| REIMAGINE-1-RENAL-IMPprogramme record | Amycretin | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURMOUNT-4-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2024 | Very low |
| SURMOUNT-OSA-1-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-ADHERENCEprogramme record | Tirzepatide | Phase 3 | Reported | Observational | — | 2024 | Very low |
| SURVO-PH2-OBESITY-OLEprogramme record | Survodutide | Phase 2 | Reported | Single-arm open-label | — | 2024 | Very low |
| PETRE-PH1B-BIOMARKERprogramme record | Petrelintide | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| REIMAGINE-1-PKprogramme record | Amycretin | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
page 2 of 9